Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA
Pharma Mirror
FEBRUARY 11, 2021
In late 2018, National OncoVenture (NOV), a government-funded virtual oncology drug development program in Korea, approached Samsung Biologics for the development of EU101(NOV1801), an anti-4-1BB therapeutic monoclonal antibody provided by Eutilex (KOSDAQ:263050). We are extremely glad to.
Let's personalize your content